Federal Court in Canada Upholds Pfizer's Norvasc Patent; Decision Prevents Launch of Generic Amlodipine Besylate Product by Pharmascience until 2010
Thursday, April 17, 2008 - 02:54am
(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court has upheld a Pfizer patent covering amlodipine besylate, the active ingredient in Norvasc. The court issued an order prohibiting regulatory approval of Pharmascience’s proposed product in Canada until Pfizer’s amlodipine besylate patent - Canadian Patent No. 1,321,393 - expires in August 2010. Pharmascience may appeal the decision to the Federal Court of Appeal of Canada.
The company noted that legal challenges to this patent in Canada by other generic manufacturers are still pending.
Pfizer Inc
Chris Loder, 212-733-7897